AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
Intelligent Ultrasound Group plc received a cash offer from Surgical Science Sweden AB, valuing the company at £45.2 million, with IP Group set to gain £8.8 million, reflecting a 100% uplift in its carrying value.
Abliva AB, valued at SEK 725.3 million (£52.4 million), received a cash offer from Pharming Technologies BV, with IP Group's 9.5% stake yielding £5 million and a 284% uplift in NAV.
The combined cash proceeds from both deals amount to £13.8 million, reinforcing IP Group's successful strategy in high-potential life sciences investments.
IP Group plc (LSE:IPO), an investment company focused on groundbreaking science and innovation, has announced significant developments within its life sciences portfolio. Two of its quoted holdings, Intelligent Ultrasound Group plc and Abliva AB, have received cash offers, signaling substantial financial returns for the Group.
Intelligent Ultrasound Group plc, in which IP Group holds a 20.8% stake, has attracted a cash offer from Surgical Science Sweden AB, valuing the company at approximately £45.2 million. This deal is expected to yield £8.8 million in cash for IP Group, reflecting a remarkable £4.4 million (100%) uplift in its carrying value compared to the last-reported net asset value (NAV) as of June 30, 2024. The proceeds will replace a previously anticipated distribution linked to the sale of Intelligent Ultrasound's AI business. Finalization of the transaction is contingent on shareholder approval and other customary conditions, with IP Group promising further updates upon completion.
Similarly, Abliva AB, a biotechnology company focused on treatments for mitochondrial diseases, has received a cash offer from Pharming Technologies BV. This offer values Abliva at approximately SEK 725.3 million (£52.4 million). IP Group, which holds a 9.5% stake in Abliva, stands to gain £5 million from the deal. This represents a 1.5x return on investment and a £3.7 million (284%) uplift from its last-reported NAV as of June 30, 2024. Completion of this transaction is also subject to customary conditions, and further updates will follow once finalized.
These developments underscore IP Group's success in identifying and nurturing high-potential life sciences ventures. The anticipated cash proceeds, totaling £13.8 million across the two transactions, highlight the Group’s ability to deliver significant value to its stakeholders through strategic investments in breakthrough innovation.
